A systematic review of preconception predictors of pregnancy outcomes in women with systemic lupus erythematosus (SLE) highlighted lupus nephritis, chronic hypertension, SLE disease activity and secondary antiphospholipid syndrome as predictors of adverse pregnancy outcomes. Pregnancies in women with SLE have historically been described as challenging, both because of the risk of disease flare and of adverse pregnancy outcomes.
Dr. John Cush RheumNow
1 year 11 months ago
Severe Alopecia Areata or Universalis - if you stop the JAK inhibitor, Hair loss occurs quickly, but can be recaptured. Severe Alopecia Areata. Substudy of the baricitinib BRAVE-AA1 RCT, 80% of those who D/C vs 8% of those continuing, lost BARI benefits https://t.co/YcfmegdvK6 https://t.co/GIwVy4ac6U
A pilot study assessed pulse methoprednisolone with weekly subcutaneous tocilizumab (TCZ) in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued.
Dr. John Cush RheumNow
1 year 11 months ago
Global Biologics Market size is valued at USD 408.5 billion in 2023 and is projected to grow ~8.25% annually. https://t.co/2RTHIgJOP5 https://t.co/gfndut5wc0
Dr. John Cush RheumNow
1 year 11 months ago
Higher Cancer Rates (8.16.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on https://t.co/V10S4oVFsv, noting his concerns about diet, cancer, ILD, death and dosing challenges.
https://t.co/thNOPkYWRM https://t.co/ZFwvE80e7Q
Dr. John Cush RheumNow
2 years ago
From 25K prediabetics, 1,521 had serial serum Uric acid measures. Predictors of increaed SU levels included Older age, male sex, greater BMI, and higher HbA1c. Those w/ a BMI ≥30 kg/m2 exhibited higher SU levels https://t.co/ztp8M781Dw https://t.co/PNaZxMIOlG
Dr. John Cush RheumNow
2 years ago
100 top-cited studies in #SLE. 60% from USA; half focused on underlying mechanisms
#1 1982 1982 Revised Criteria for.. Classification ..SLE
#2 Updated ACR Criteria...
#3 Derivation of SLEDAI https://t.co/g3fcUqtsct https://t.co/HlGfGC4aci
Donald Thomas, MD lupuscyclopedia
2 years ago
🔥 One of the most important articles of the year showing medical evidence for disease-modifying (organ damage prevention) therapies in #SLE #lupus:
CLICK 👉 https://t.co/Qmia9Gc8mu
Kudos to the authors for such an important piece of work. Open up the table in the article and… https://t.co/z9osFAavud https://t.co/lWjkwMEHrq
Dr Ai Lyn Tan DrAiLynTan
2 years ago
IgG4-related disease
Nearly any organ can be affected
▶️Salivary glands
▶️Lacrimal glands
▶️Orbit
▶️Pancreatobiliary system
▶️Lung
▶️Kidney
▶️Retroperitoneum
👉🏽https://t.co/758F5iuYwT
via @RheumJnl https://t.co/ipONrygHmc
Dr. Antoni Chan synovialjoints
2 years ago
New! 📣Best Practice Guidelines for the management of Haemophagocytic Lymphohistiocytosis (HLH) aka Macrophage Activation Syndrome (MAS) from @NHSGIRFT @RheumatologyUK Remember the 3Fs Fever, Falling Counts, Ferritin and follow the HLH pathway to guide management… https://t.co/8oDyUbsm9W https://t.co/S0MDi3TkNk
Could disease control in active systemic lupus erythematosus (SLE) patients be improved by the sequential use of subcutaneous belimumab (BEL) and intravenous rituximab (RTX)? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
Dr. John Cush RheumNow
2 years ago
Metanalysis of 50 RCTs (3,231 pts w/ lupus nephritis (LN) related starting pred dose to rates of complete response (CR), serious infections, & death. PO pred 25 mg/D assoc w/ 20%, 3.2% & 0.2%, respectively. Pred 60 mg/day incr rates to 35%, 12% & 2.7% https://t.co/6FH9BWsmaz https://t.co/0cQPAIuvRw
Dr. John Cush RheumNow
2 years ago
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to SEC 300 mg, but failed to show improvement by week 52.
https://t.co/EJvoBlW9or https://t.co/tYb1fIA3pw
Dr. John Cush RheumNow
2 years ago
Metanalysis of 12 studies shows that being edentulous (or having < 20 teeth) was associated w/ higher risk (HR 1.66; 1.32–2.09) critical confounders also confirmed that tooth loss as a risk factor for Cardiovascular mortality (HR=1.52, 95% CI: 1.28–1.80) https://t.co/PStGlxmCC3 https://t.co/ZDzaytj9dY
Dr. John Cush RheumNow
2 years ago
Metanalysis of 16 RCTs shows febuxostat reduces the risk of kidney events (RR = 0.56, 95% CI 0.37-0.84, p = 0.006) and a slower decline in eGFR (vs controls) https://t.co/9YAxTrHFVQ https://t.co/ZyRE7R6P4a
